Squarepoint Ops LLC Invests $544,000 in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Squarepoint Ops LLC bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 80,421 shares of the company's stock, valued at approximately $544,000.

A number of other hedge funds and other institutional investors have also modified their holdings of RXRX. Softbank Group CORP. purchased a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth about $99,152,000. Novo Holdings A S bought a new stake in Recursion Pharmaceuticals in the fourth quarter valued at about $68,375,000. Vanguard Group Inc. increased its holdings in Recursion Pharmaceuticals by 40.1% in the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock valued at $229,908,000 after buying an additional 9,737,196 shares during the last quarter. Norges Bank bought a new stake in Recursion Pharmaceuticals in the fourth quarter valued at about $23,429,000. Finally, Laurion Capital Management LP bought a new stake in Recursion Pharmaceuticals in the fourth quarter valued at about $16,611,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ:RXRX traded down $0.34 during trading on Thursday, hitting $4.57. 32,620,085 shares of the company traded hands, compared to its average volume of 14,024,680. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of -2.99 and a beta of 0.84. The business's fifty day moving average is $4.82 and its 200-day moving average is $6.36. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The company had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period last year, the company posted ($0.39) earnings per share. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on RXRX. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Needham & Company LLC lowered their price objective on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Morgan Stanley lowered their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Finally, Leerink Partners lowered their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $7.60.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.